Septin 9 methylation is often regarded as a model for future work [56, 57], and it is notable that there are some large studies [58] within the evidence base for the use of this marker in colorectal cancer, often used in addition to other markers, such as faecal occult blood testing (FoBT) or faecal immunohistochemical testing (FIT). This evidence concerns the gene SEPTIN9 and colorectal cancer.